Galapagos signs research agreement with UCL
Galapagos NV announced that is has signed a drug discovery research agreement with UCL (University College London). Galapagos' BioFocus DPI service division will perform medicinal chemistry services for a UCL research project. It is also intended that BioFocus DPI will offer UCL ADME] screening facilities during the appropriate stages of the work. Total contract value for Galapagos is expected to reach more than EUR1.8 million over the course of the two-year agreement.
UCL has an ongoing drug discovery program for the treatment of vascular collapse during sepsis (collapsing of blood vessels due to systemic infection by a pathogen). BioFocus DPI will provide medicinal chemistry services to progress UCL's lead series through to pre-clinical testing. In addition UCL will also have the opportunity to utilize BioFocus DPI ADME screening services and will receive access to a selection of compounds in BioFocus DPI's SoftFocus collection to facilitate the identification of new chemical starting points for this drug discovery program.
Other news from the department science
